Cambridge Investment Research Advisors, Inc. Madrigal Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 1,148 shares of MDGL stock, worth $337,695. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,148
Previous 1,151
0.26%
Holding current value
$337,695
Previous $355,000
7.04%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding MDGL
# of Institutions
368Shares Held
23.2MCall Options Held
979KPut Options Held
432K-
Janus Henderson Group PLC London, X02.21MShares$649 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$618 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$595 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$586 Million10.82% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$581 Million7.8% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.03B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...